Non Small Cell Lung Cancer (NSCLC)

Stage I-III: Unresectable

Stage I-III

Treated w/ SBRT +/- adjuvant chemo

LUN0115
Phase II Adjuvant Durvalumab in Early Stage NSCLC Patients with ctDNA Minimal Residual Disease

PI: Neal Stanford

Stage II-III

LUN0114
Personalized Escalation of Consolidation Treatment After ChemoRT & Immunotherapy in Stage IIIB/III NSCLC

PI: Neal Stanford

LUN0118
Phase III Atezolizumab & Targilumab vs Durvalumab in Stage III NSCLC w/o Progression After Chemoradiation

PI: Wakelee F. Hoffmann-La Roche Ltd

KEY

Pending
Open for Enrollment
Optional Path
Extension Study
Trial Posting
Immunotherapy
Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu